Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Treatment-Resistant Depression in Veterans
NCT07226232Phase 3Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Aug 2026
- Primary completion
- Dec 2030
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of psilocybin in treatment-resistant depression (TRD), sponsored by VA Office of Research & Development. Started Aug 2026; status: recruiting.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT07226232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226232.